Trial Profile
ICI-VPH: Impact of dosing schedules with Human papillomavirus vaccine [Impact Des Calendriers d'Immunisation Contre Les HPV]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 May 2022
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Human papillomavirus infections
- Focus Therapeutic Use
- Acronyms ICI-VPH
- 21 Apr 2022 Status changed from active, no longer recruiting to completed.
- 02 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 04 Feb 2015 Planned number of patients is 4000 as reported by ClinicalTrials.gov record.